During Lung Cancer Awareness Month, Cancer Research UK is promoting awareness and support for lung cancer initiatives, highlighting the importance of early detection.

Scientists have developed a groundbreaking urine test that may indicate early signs of lung cancer, addressing the critical challenge of late-stage diagnoses.

The research, led by Professor Ljiljana Fruk and Dr. Daniel Munoz Espin from the University of Cambridge's Department of Chemical Engineering and Biotechnology and the Early Cancer Institute, has shown promising results in mice.

This innovative test targets proteins from senescent cells, commonly referred to as 'zombie cells', which are alive but cannot grow or divide, contributing to tissue damage and promoting cancer development.

Professor Fruk explains that damaged cells release signals that reprogram surrounding tissue, creating an environment conducive to cancer.

The study aims to provide a cost-effective alternative to expensive imaging scans for early cancer detection, particularly for high-risk groups.

Lung cancer is the third most common cancer in the UK, with approximately 50,000 new diagnoses each year, yet only 10% of patients survive a decade post-diagnosis.

Dr. Iain Foulkes from Cancer Research UK emphasizes the project's potential to enhance survival rates and improve the quality of life for cancer patients.

Lung cancer remains the leading cause of cancer-related deaths globally, accounting for about 1.8 million fatalities annually, with survival rates particularly low for advanced stages.

The researchers have successfully tested the urine test on mice and are preparing to begin human trials soon.

Researchers plan to validate the test further and eventually extend its application to other cancers, including breast, melanoma, and pancreatic cancer.

Cancer Research UK has invested over £231 million in lung cancer research over the past decade, significantly contributing to advancements in the field.